Disclosed herein are systems, devices, and methods for thrombolysis. For example, a medical device for thrombolysis can include a conduit, a supply reservoir, and a waste reservoir. The conduit can be configured to insert into a lumen of a venous access device having an intraluminal clot. The conduit can include a supply lumen configured to convey an aqueous thrombolytic composition from the supply reservoir through an opening in a distal-end portion of the conduit to the intraluminal clot. The waste reservoir can be configured to collect waste from the lumen of the venous access device including fibrin fragments, platelets, red blood cells, or spent solution of the thrombolytic composition used to break down the intraluminal clot. Administering a thrombolytic composition in accordance with the disclosed systems, devices, and methods can break down clots more quickly than at least the common 3-way stopcock method.

Disclosed is a method of extracting, from the patient's own blood, enriched platelet factors, or EnPLAF, storable supernatant, void of live blood cells, utilized for treatment of said patient's medical conditions, including but not limited to pain management, aesthetic rejuvenation, bone, muscle and soft tissue healing.

Methods and systems for reducing bacterial contamination of platelets are disclosed. The methods and systems disclosed herein provide for the processing of a pre-determined volume of whole blood so as to reduce the risk that platelets separated and collected from the whole blood have a reduced risk of bacterial contamination.

An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.

Provided is a blood component separation device and related method, each capable of separating a blood component from blood and rapidly performing a virus inactivation process on the separated blood component. The blood component separation device includes a blood component separation section, provided in a centrifuge, configured to separate a blood component from blood by centrifugation, a diluting section configured to dilute, in a diluent containing riboflavin, concentrated red blood cells separated by the blood component separation section, and a UV light emitting unit configured to perform a virus inactivation process by exposing the concentrated red blood cells thus diluted to the UV light.

A platelet agitator includes a base and a frame. The frame moves laterally relative to the base at variable speeds. The agitator further includes a controller and a user interface in communication with the controller. The user interface has a discontinuous input device that has at least a portion of adjustment range that is non-linear compare to the remainder of the adjustment range.

Embodiments of the invention include instruments and methods useful in preparing and delivering graft material to a surgical site. Some embodiments may particularly be directed to forming a graft from a blood clot and accurately and effectively handling and delivering the graft to a surgical site. Graft material may include blood components such as clotted fibrin derived from a patient's or a donor's blood.

The present invention relates to a platelet rich plasma (PRP) extracting device and extracting method using the same, and more particularly, to a platelet rich plasma (PRP) extracting device capable of quickly and effectively extracting the highly concentrated PRP from centrifuged blood by a simple manipulation.

The present invention discloses a sterile PRP separation kit that has compartmentalized container having a cover that allows for a stage-specific exposure of sterile components of the sterile PRP separation kit housed within stage-specific compartments to a non-sterile environment commensurate with a specific stage of operation of a separation process of PRP. The sterile PRP separation kit includes a PRP tube with segregated portals for injection of blood into the PRP tube, aspiration of PRP from the PRP tube, and for maintaining an interior pressure of the PRP tube at equilibrium with ambient pressure during both injection and aspiration.

Blood is conveyed from a source into a separator, which separates at least one target blood component from the blood. The target blood component is then conveyed out of the separator, with the procedure continuing until an initial target amount of blood to be processed has been conveyed from the source into the separator and the target blood component separated from the initial target amount of blood to be processed has been conveyed out of the separator as an actual yield of the target blood component. An adjusted target amount of blood to be processed is then determined based at least in part on the difference between a target yield of the target blood component and the actual yield. The initial target amount of blood to be processed is then replaced with the adjusted target amount of blood to be processed when next executing the procedure.